This open-label, single-group phase 2 study enrolled 37 patients with recurrent or unresectable giant-cell tumor of bone to evaluate whether denosumab — a fully human anti-RANKL monoclonal antibody — could suppress tumor growth and giant-cell activity. The primary endpoint was tumor response defined as ≥90% elimination of giant cells on histology or no radiological progression by week 25.
When you encounter a patient with recurrent or anatomically unresectable GCT (pelvis, spine, sacrum) where surgery would cause unacceptable morbidity, denosumab 120 mg monthly is a high-response-rate systemic option — and the near-uniform histological response also makes it worth considering neoadjuvantly to downsize resectable tumors before surgery.
This open-label, single-group phase 2 study enrolled 37 patients with recurrent or unresectable giant-cell tumor of bone to evaluate whether denosumab — a fully human anti-RANKL monoclonal antibody — could suppress tumor growth and giant-cell activity. The primary endpoint was tumor response defined as ≥90% elimination of giant cells on histology or no radiological progression by week 25.
When you encounter a patient with recurrent or anatomically unresectable GCT (pelvis, spine, sacrum) where surgery would cause unacceptable morbidity, denosumab 120 mg monthly is a high-response-rate systemic option — and the near-uniform histological response also makes it worth considering neoadjuvantly to downsize resectable tumors before surgery.